Drug profile

The FDA adverse-event record for Oral Bbpi Lb/Lv

54 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Oral Bbpi Lb/Lv. Species, reactions, and outcomes follow.

#1071 of 2,679
by report volume (all drugs)
54
adverse-event reports
3.7%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Oral Bbpi Lb/Lv ranks #1065 of 2679 by total reports (54) and #865 of 1130 by death-coded share (3.7%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1065
This drug, reports of 2679
#865
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Oral Bbpi Lb/Lv has 54 reports now versus 47 in that prior snapshot: 7 more (14.9%).

Report change
+7
Death-coded reports
+0
Death-coded share
−0.6 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Oral Bbpi Lb/Lv changes

Signature read: Oral Bbpi Lb/Lv's 3.7% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
54
Total Reports
2
Deaths Reported
3.7%
Death-coded share of reports

Active Ingredients

Oral Bbpi Lb/Lv

Administration Routes

OralSubcutaneous

Species Affected

Dog 54

Most Affected Breeds

Crossbred Canine/dog 15
Retriever - Labrador 8
Chihuahua 3
Bulldog - French 3
Retriever - Golden 2
Poodle - Miniature 2
Siberian Husky 2
Shepherd Dog - Australian 2
Shih Tzu 2
Unknown 2

Most Reported Reactions

Emesis (multiple) 15
Lethargy (see also Central nervous system depression in Neurological) 11
Hypersensitivity reaction 11
Hives (see also Skin) 11
Anaphylaxis 10
Vomiting 10
Facial swelling (see also Skin) 9
Panting 7
Elevated alanine aminotransferase (ALT) 6
Not eating 5
Diarrhoea 5
Breathing difficulty 4

Outcome Breakdown

Recovered/Normal
26 (48.1%)
Ongoing
17 (31.5%)
Outcome Unknown
7 (13.0%)
Recovered with Sequela
2 (3.7%)
Died
1 (1.9%)
Euthanized
1 (1.9%)

Oral Bbpi Lb/Lv: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Nationwide drugs with similar profiles

Two openFDA-derived peer sets for Oral Bbpi Lb/Lv, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Oral Bbpi Lb/Lv (#1071 of 2,679 by report volume); death-coded 3.7%. PlainBreed drug row · death-coded share stamp 3.7% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →